I’ve sat across from women in their late 40s who had both ovaries removed. Endometriosis. A cyst that would not resolve. A BRCA mutation. Then they got sent home with nothing. No hormone therapy. No conversation about what surgical menopause actually does to a body that was cycling normally the week before. Just a pamphlet about hot flashes and a follow-up in six months.
That is not medicine. That is abandonment with a prescription pad nowhere in sight.
A new study out of Denmark just gave us the clearest answer yet on what ovary removal hormone therapy actually does to survival. Researchers tracked 876,805 women for a median of 14.3 years. For women who lost their ovaries in their 40s or early 50s, the number is not subtle.
The Study Nobody’s Doctor Is Reading Yet
A 2026 study in BMJ pulled nationwide Danish health registries. Researchers followed women born between 1950 and 1977, starting at age 45. Of the 876,805 women in the cohort, 104,086 (11.9%) filled at least one prescription for menopausal hormone therapy. Over the follow-up period, 47,594 women (5.4%) died.
Here’s what they found: hormone therapy use showed no increased risk of death at any duration, even after 10 or more years. Not a small increase. Not a delayed one. None at all.
That finding alone should retire the lingering fear left over from older, smaller trials. But the study’s most useful number lives in one specific subgroup: women who had both ovaries removed, for reasons unrelated to cancer, between ages 45 and 54.
The 34% Difference That Should Change How Surgical Menopause Gets Treated
Women in that subgroup who used hormone therapy had a 27% to 34% lower risk of death compared to women who did not. Translation: the median age at death was 60.9 for hormone therapy users and 56.6 for non-users. That is a four-year gap, in a population that already lost its natural hormone timeline to surgery.
What Ovary Removal Actually Does to Your Body
Ovary removal surgery, the clinical term is oophorectomy, does not gently transition a woman into menopause. Instead, it cuts off estrogen and progesterone production overnight, at whatever age surgery happens. A 42-year-old having her ovaries removed for a benign cyst faces the same hormonal cliff as a woman going through natural menopause at 51. Except hers arrives nine years early. And she gets no gradual perimenopause to adjust to it.
Women come to me after this kind of surgery describing symptoms their surgeon never warned them about. Sleep that will not hold. Joints that ache for no reason. A mental fog that makes them question their own competence at work. Nobody connected those symptoms to the surgery. Nobody offered hormone therapy as a first option instead of an afterthought.
Why Timing and Type Both Matter
The Danish data also broke down which types of hormone therapy performed best. The lowest mortality showed up in women using transdermal types, patches or gels through the skin, estrogen alone for women without a uterus, or cyclic progestogen regimens. Women who started therapy at 52 or older also fared better than those who started after a long gap without treatment.
The Menopause Society has already moved its guidance away from the rigid age and time cutoffs of the past decade. So if you had your ovaries removed and were told hormone therapy was too risky, or that you had missed the window, that advice was not built on current evidence. It was built on outdated fear.
What This Looks Like in Practice
I had a patient last year, ovaries removed at 44 for recurrent cysts, who spent three years cycling through antidepressants. Nobody connected her insomnia and brain fog to the surgery. We started transdermal estrogen instead. Within two months, she told me she felt like herself again for the first time since the operation. That is not an anecdote I share lightly. It is what the data now backs up in a population of nearly a million women.
Key Takeaways
- A Danish registry study of 876,805 women found no increased mortality risk from hormone therapy at any duration, including 10-plus years.
- Women who had both ovaries removed between ages 45 and 54, for non-cancer reasons, had a 27% to 34% lower risk of death on hormone therapy.
- The median age at death: 60.9 for hormone therapy users in this subgroup, versus 56.6 for non-users.
- Transdermal types, estrogen alone, and cyclic progestogen regimens showed the lowest mortality risk.
- Starting hormone therapy at 52 or older still produced a survival benefit. There is no hard cutoff.
Frequently Asked Questions
What counts as surgical menopause? Surgical menopause happens when both ovaries are removed, through a procedure called oophorectomy, before natural menopause. Unlike the gradual hormone decline of perimenopause, surgical menopause drops estrogen and progesterone abruptly, often within days.
Am I too old to start hormone therapy after ovary removal? Based on this data, no. Women who started hormone therapy at 52 or older still showed a survival benefit. So the window for starting therapy is far wider than most women get told in a standard consult.
Getting the Right Type and Timing
Is transdermal hormone therapy different from pills? Yes, and the difference matters. Transdermal estrogen, delivered through a patch or gel, bypasses first-pass liver metabolism. In this study, transdermal types were tied to the lowest mortality, alongside estrogen-only regimens and cyclic progestogen.
What if my ovaries were removed because of a BRCA mutation or cancer risk? This particular study focused on non-cancer indications, so these numbers do not directly apply to BRCA-related surgery. That said, the underlying hormone loss is identical. It deserves its own personalized workup with a doctor who understands both your cancer risk and your hormone needs. Do not accept a blanket no without that conversation.
What to Ask Your Doctor
What should I ask for if my doctor already said no to hormone therapy? Ask specifically about transdermal estrogen. Ask whether your case truly falls outside current evidence, or whether you got a generalized answer built on outdated guidance. And request a referral to a menopause-trained provider if the conversation stalls there.
How does Living Well Dallas or Menrva Health evaluate this? Both Living Well Dallas and Menrva Health start with a full hormone and health history, not a reflexive no. We look at your surgical history, your current symptoms, and your personal risk factors together. Then we build a treatment plan around your actual body, not a decades-old assumption about who qualifies.
Dr. Betty’s Bottom Line
I’ve built a career on the gap between what the data says and what women actually get told in a five-minute appointment. This study closes that gap with real numbers: 27% to 34% lower risk of death, a four-year difference in median age at death, and zero increased mortality risk overall, even after a decade of use.
If you had your ovaries removed and someone told you hormones were too risky, or that you had waited too long, I want you to hear this clearly. That advice was not built on this evidence. It was built on fear left over from a study population that looked nothing like you.
Surgical menopause is not a life sentence to hot flashes and brain fog. It is a hormone deficiency with a name and a mechanism. And now, it has a large body of survival data behind treating it properly.
In-person care at Living Well Dallas is available for patients in the Dallas area who want a full hormone workup after ovary removal surgery. Menrva Health offers the same root-cause workup through telehealth in all 50 states, so distance is never the reason you go untreated.
Source: Mikkelsen AP, Bergholt T, Lidegaard Ø, Scheller NM. Menopausal hormone therapy and long term mortality: nationwide, register based cohort study. BMJ. Published February 18, 2026. PMID: 41708152.